Thus, upregulation of ESRP1/ESRP2 gene expression in aggressive tumours, by either gene amplification or in response to androgens could be different means to the same end, and drive the progression of aggressive prostate cancer in a similar way. The gene discussed is ESRP1; the disease is neoplasm.